logo
Plus   Neg
Share
Email

Conatus Pharmaceuticals Posting Strong Gain In Afternoon Trading

Shares of Conatus Pharmaceuticals (CNAT) have shown a strong move to the upside on Friday, with the biotechnology company climbing by 7.9 percent. Conatus reached a nearly two-month intraday high earlier in the session.

The jump by Conatus comes after the company announced that its exclusive license with Novartis (NVS) for the global development and commercialization of emricasan has become effective upon the receipt of a $7 million payment.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA announced on its website that pharma major Pfizer, Inc. issued recall of two lots of tablets meant to treat acute migraine in adults for concerns over bacteria infection. The pharma company is recalling two lots of Relpax (eletriptan hydrobromide) 40 mg tablets for potential presence of Genus Pseudomonas and Burkholderia bacteria. Cosmetics company Revlon Inc. (REV) is reportedly considering a potential sale of parts or all of its business. According to Bloomberg, Revlon has retained financial advisers from Goldman Sachs Group Inc. to explore strategic alternatives. No deal has been reached yet, but Revlon is exploring all... China's Lenovo Group Ltd. warned it may have to raise prices of its products if the U.S. moves ahead with the decision to impose additional tariffs on Chinese goods, according to a report by Reuters. The warning by Lenovo, the world's largest PC maker, comes amid the escalating trade war between the U.S. and China that has raised concerns about the global economic outlook.